CMPS is trading 5% down at $13.44 as the stock extends its pullback following a sharp multi-week rally and recent profit-taking.
- The decline is attributed to technical consolidation and a cooling off period after significant gains, with no fresh company-specific news reported today.
- Compass Pathways’ clinical and regulatory outlook remains unchanged, though the stock is showing sensitivity to broader risk-off moves in high-beta biotech names.